Tscan Therapeutics Inc (TCRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
David P. Southwell
Employees:
100
830 WINTER STREET, WALTHAM, MA 02451
857-399-9500

TScan Therapeutics, Inc. develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.

Data derived from most recent annual or quarterly report
Market Cap 64.16 Million Shares Outstanding24.03 Million Avg 30-day Volume 163.562 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.63
Price to Revenue7.1925 Debt to Equity0.1559 EBITDA-77.05 Million
Price to Book Value0.6192 Operating Margin-503.2604 Enterprise Value-61.098 Million
Current Ratio6.897 EPS Growth-1.332 Quick Ratio6.856
1 Yr BETA 0.3738 52-week High/Low 6.03 / 1.45 Profit Margin-496.0875
Operating Cash Flow Growth-27.8162 Free Cash Flow to Firm (FCFF) TTM -63.244 Million Free Cash Flow to Equity (FCFE) TTM-60.865 Million
Altman Z-Score-0.3689
Earnings Report2023-11-08

Are you looking for this stock instead?

View SEC Filings from TCRX instead.

View recent insider trading info

Tscan Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TCRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TCRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-07-24 by DWORAK LEIDEN
  • 3: filed on 2023-07-24 by DWORAK LEIDEN
  • 4: filed on 2023-06-15 by BARTON DEBORA
  • 4: filed on 2023-06-15 by GRUIA GABRIELA
  • 4: filed on 2023-06-15 by SILVER BRIAN M.
  • 4: filed on 2023-04-10 by KLENCKE BARBARA
  • 3: filed on 2023-04-10 by KLENCKE BARBARA
  • 4: filed on 2023-02-06 by SOUTHWELL DAVID P
  • 4: filed on 2023-02-06 by MACBEATH GAVIN
  • 4: filed on 2023-02-06 by ZDRAVESKI ZORAN

    • Events (8k)

  • 8-K: filed on 2023-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-25:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-31:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-16:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-15:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DWORAK LEIDEN CHIEF ACCOUNTING OFFICER

    • Officer
    		 5,692 2023-07-21 2

    BAKER BROS. ADVISORS LP

    667, L.P.

    BAKER FELIX

    BAKER JULIAN

    BAKER BROS. ADVISORS (GP) LLC

    BAKER BROTHERS LIFE SCIENCES LP

    • Director
    		 0 2023-06-13 2

    BARBERICH TIMOTHY J

    • Director
    		 0 2023-06-13 2

    DORTON KATINA

    • Director
    		 0 2023-06-13 1

    KLENCKE BARBARA

    • Director
    		 0 2023-06-13 3

    MACBEATH GAVIN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-06-13 2

    ZDRAVESKI ZORAN CHIEF LEGAL OFFICER

    • Officer
    		 0 2023-06-13 2

    GRUIA GABRIELA

    • Director
    		 0 2023-06-13 1

    SILVER BRIAN M. CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-06-13 2

    BARTON DEBORA CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-06-13 2

    LYNX1 CAPITAL MANAGEMENT LP

    NICHOLS WESTON

    • 10% Owner
    		 5,250,000 2023-05-31 2

    ECOR1 CAPITAL, LLC

    • 10% Owner
    		 5,000,000 2023-05-26 1

    SOUTHWELL DAVID P CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-02-02 1

    DESMARAIS WILLIAM CHIEF BUSINESS OFFICER

    • Officer
    		 30,000 2022-07-25 0

    HAREL ITTAI

    • Director
    		 9,146 2022-06-01 0

    WESTPHAL CHRISTOPH H

    • 10% Owner
    		 2,315,423 2021-07-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 22:15:05 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 21:45:03 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 21:15:04 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 20:45:04 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 20:15:05 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 19:45:03 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 19:15:04 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 18:45:04 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 18:15:04 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 17:45:03 UTC 0.0 0.0 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 17:15:03 UTC 0.0 0.0 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 16:45:04 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 16:15:05 UTC -8.1808 13.5008 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 15:45:04 UTC -8.1797 13.4997 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 15:15:03 UTC -8.1797 13.4997 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 14:45:03 UTC -8.2059 13.5259 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 14:15:03 UTC -8.2059 13.5259 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 13:45:03 UTC -8.206 13.526 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 13:15:05 UTC -8.206 13.526 200000
    TSCAN THERAPEUTICS INC TCRX 2023-09-27 12:45:05 UTC -8.206 13.526 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund TCRX -300.0 shares, $-750.0 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments